QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
QQQ   425.76 (-0.02%)
AAPL   167.88 (-0.07%)
MSFT   408.36 (-0.84%)
META   506.07 (+2.41%)
GOOGL   155.94 (+0.30%)
AMZN   181.21 (-0.04%)
TSLA   150.48 (-3.20%)
NVDA   845.83 (+0.65%)
AMD   154.69 (+0.44%)
NIO   3.99 (+2.05%)
BABA   69.24 (+0.61%)
T   16.16 (+0.25%)
F   12.09 (+0.42%)
MU   116.92 (+0.51%)
GE   157.72 (+1.32%)
CGC   7.06 (+8.78%)
DIS   113.39 (+0.40%)
AMC   2.79 (-6.38%)
PFE   25.35 (-0.28%)
PYPL   63.07 (-0.30%)
XOM   119.05 (+0.35%)
Free Trial

Corvus Pharmaceuticals (CRVS) News Today

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)
Free CRVS Stock Alerts
$1.37
+0.01 (+0.74%)
(As of 10:13 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
MarketBeat logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update
americanbankingnews.com - April 18 at 5:54 AM
finance.yahoo.com logoHere's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
finance.yahoo.com - April 17 at 12:53 PM
marketbeat.com logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 6.0% in March
marketbeat.com - April 16 at 4:34 PM
MarketBeat logoCorvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Below Fifty Day Moving Average of $2.01
americanbankingnews.com - April 13 at 4:42 AM
globenewswire.com logoCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
globenewswire.com - April 9 at 4:01 PM
marketbeat.com logoCorvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)
marketbeat.com - April 4 at 9:14 AM
marketbeat.com logoCantor Fitzgerald Reaffirms Overweight Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
marketbeat.com - April 1 at 12:23 PM
marketbeat.com logoMizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
marketbeat.com - March 27 at 2:13 PM
seekingalpha.com logoCorvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 21 at 5:14 PM
finance.yahoo.com logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 21 at 5:14 PM
finanznachrichten.de logoCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 21 at 7:29 AM
marketbeat.com logoCorvus Pharmaceuticals (NASDAQ:CRVS) Price Target Lowered to $7.00 at Oppenheimer
marketbeat.com - March 20 at 8:22 AM
finance.yahoo.com logoQ4 2023 Corvus Pharmaceuticals Inc Earnings Call
finance.yahoo.com - March 20 at 6:37 AM
stockhouse.com logoCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
stockhouse.com - March 19 at 10:03 PM
globenewswire.com logoCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 19 at 4:02 PM
marketbeat.com logoCorvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on Tuesday
marketbeat.com - March 18 at 7:39 AM
finance.yahoo.com logoCRVS Apr 2024 4.000 put
finance.yahoo.com - March 16 at 3:41 PM
globenewswire.com logoCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
globenewswire.com - March 13 at 4:02 PM
finance.yahoo.com logoWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
finance.yahoo.com - March 9 at 1:52 PM
marketbeat.com logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in February
marketbeat.com - March 4 at 11:57 AM
finance.yahoo.com logoCRVS Mar 2024 3.000 put
finance.yahoo.com - February 17 at 7:36 AM
msn.com logoCorvus Edges up on Disclosing Data
msn.com - February 12 at 6:33 PM
finance.yahoo.com logoCorvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
finance.yahoo.com - February 12 at 1:33 PM
marketwatch.com logoCorvus Pharmaceuticals Shares Rise on Orphan Drug Designation
marketwatch.com - February 8 at 6:17 PM
msn.com logoCorvus lymphoma drug gets FDA orphan drug status
msn.com - February 8 at 6:17 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
finance.yahoo.com - February 8 at 6:17 PM
finance.yahoo.com logoCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
finance.yahoo.com - February 6 at 9:12 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
finance.yahoo.com - January 23 at 7:04 PM
finance.yahoo.com logoIndividual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week
finance.yahoo.com - January 5 at 9:48 AM
markets.businessinsider.com logoMaintaining Hold Rating on Corvus Pharmaceuticals Amid Steady but Unspectacular Clinical Progress
markets.businessinsider.com - December 13 at 11:15 PM
msn.com logoAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
msn.com - December 7 at 3:48 PM
finance.yahoo.com logoIs Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?
finance.yahoo.com - November 21 at 12:34 PM
morningstar.com logoCorvus Pharmaceuticals Inc CRVS
morningstar.com - November 9 at 8:39 AM
finance.yahoo.com logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 8 at 2:58 PM
finance.yahoo.com logoQ3 2023 Corvus Pharmaceuticals Inc Earnings Call
finance.yahoo.com - November 8 at 9:57 AM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 7 at 5:35 PM
finance.yahoo.com logoCorvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
finance.yahoo.com - November 2 at 10:24 AM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
finance.yahoo.com - November 1 at 11:19 PM
finance.yahoo.com logoCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
finance.yahoo.com - October 31 at 8:25 PM
finance.yahoo.com logoHere's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
finance.yahoo.com - October 1 at 10:16 AM
markets.businessinsider.com logoAnalysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)
markets.businessinsider.com - September 12 at 1:42 PM
fool.com logoCorvus Pharmaceuticals (NASDAQ: CRVS)
fool.com - September 8 at 8:31 PM
msn.com logoCantor Fitzgerald Reiterates Corvus Pharmaceuticals (CRVS) Overweight Recommendation
msn.com - September 7 at 7:18 PM
finance.yahoo.com logoCorvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
finance.yahoo.com - September 6 at 4:23 PM
markets.businessinsider.com logoCorvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer
markets.businessinsider.com - August 18 at 4:38 PM
marketbeat.com logoCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to Post FY2023 Earnings of ($0.50) Per Share, Cantor Fitzgerald Forecasts
marketbeat.com - August 14 at 3:51 AM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
finance.yahoo.com - August 8 at 7:44 PM
msn.com logoCircling Back On Corvus Pharmaceuticals
msn.com - August 1 at 5:09 PM
finance.yahoo.com logoCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
finance.yahoo.com - August 1 at 5:09 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
finance.yahoo.com - July 6 at 2:10 PM
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

CRVS Media Mentions By Week

CRVS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRVS
News Sentiment
▼
0.84

0.47
▲
Average
Medical
News Sentiment

CRVS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRVS Articles
This Week
▼
3

1
▲
CRVS Articles
Average Week

Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:CRVS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
IRS Loophole Gives Americans An Escape From Inflation
Birch Gold
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
He Is Giving Away Bitcoin
Crypto Swap Profits
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Rich Dad Poor Dad Author Shocks Millions With 2024 Crash Warning
American Hartford Gold Group